Clinical Efficacy of Yinchenhao Tang Combined with Sinisan in Treating Nonalcoholic Fatty Liver Disease with Hyperhomocysteinemia
10.13422/j.cnki.syfjx.20190828
- VernacularTitle: 茵陈蒿汤合四逆散治疗非酒精性脂肪肝伴高同型半胱氨酸血症临床观察
- Author:
Jian-ru FENG
1
;
Guang-yuan XU
2
Author Information
1. Beijing Shichahai Community Health Service Center, Beijing 100053, China
2. Fuxing Hospital, Capital Medical University, Beijing 100045, China
- Publication Type:Research Article
- Keywords:
nonalcoholic fatty liver disease;
hyperhomocysteinemia;
Yinchenhao Tang;
Sinisan
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2019;25(16):61-66
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To investigate the clinical efficacy of Yinchenhao Tang combined with Sinisan(YCSN) on non-alcoholic fatty liver disease (NAFLD) with hyperhomocysteinemia (HHcy). Method: Totally 126 cases of NAFLD with HHcy in Beijing Shichahai Community Health Service Center were randomly divided into NAFLD control group, traditional Chinese medicine(TCM) group, and modern medicine group, with 42 cases in each group. The TCM group was treated with YCSN orally, the modern medicine group was treated with polyene phosphatidylcholine capsules and folic acid tablets, and the NAFLD control group was treated with placebo. The course of treatment was 3 months. The clinical efficiency, liver function, Hcy, blood lipid, oxidative inflammation index and symptom score in two groups were observed before and after treatment. Result: The total effective rate of the TCM group was 92.86%, while that of the modern medicine group was 88.10%. There was no significant difference in the clinical efficiency between the two groups. There was no difference in the indexes of groups before treatment. After treatment,alanine aminotransferase (ALT), aspartate aminotransferase (AST), Hcy, total cholesterol (TC), total triglyceride (TG), low-density lipoprotein (LDL), malondialdehyde (MDA), high-sensitive C reactive protein (hs-CRP), serum creatinine (SCr), blood urea nitrogen (BUN), and symptom scores in the TCM group and the modern medicine group were significantly lower than those before the treatment (P<0.05), and lower than those in the NAFLD control group (P<0.05); and high-density lipoprotein (HDL) and superoxidase dismutase (SOD) in the TCM group and the modern medicine group significantly increased (P<0.05), and higher than those of NAFLD control group (P<0.05). Compared with the modern medicine group, ALT, Hcy, TC, TG, MDA, hs-CRP, and symptom scores in TCM group were significantly lower than those before the treatment (P<0.05), while SOD in the TCM group was significantly increased (P<0.05). Conclusion: YCSN can improve hyperhomocysteinemia, liver function, blood lipid, oxidation and inflammation in patients with NAFLD and HHcy.
